How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies?
The market for disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis (RR-MS) is highly active and commercially compelling. In spite of a small diagnosed prevalent population relative to many other neurological indications, drug-treatment rates for RR-MS are high, and neurologists emphasize early intervention and long-term treatment to improve long-term outcomes in this chronic disease. The number of disease-modifying therapies approved to treat RR-MS is expanding steadily, including the availability of multiple oral disease-modifying drugs in this historically injectable market. However, because the MS disease course is heterogeneous and therapeutic response is unpredictable, a continued need exists for more-effective, more-tolerable, and less-burdensome treatment alternatives.